RESOURCES AND SUPPORT
On this page:
VIBERZI savings program 
Tools for your practice 

For the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults

RESOURCES FOR YOUR PATIENTS AND YOUR PRACTICE

Eligible patients may save on VIBERZI!

$0*

OR

First 90-day prescription

$30*

Then pay as little as $30* for 30-, 60-, or 90-day refills.
VIBERZI is covered for 94% of commercially insured Americans.
* Depending on insurance coverage, most eligible patients may pay as little as $30 per prescription fill for each of up to 12 prescription fills. Maximum savings limit applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. This offer is not valid for cash-paying patients. Please see full Program Terms, Conditions, and Eligibility Criteria at ViberziSavings.com.
Source: MMIT, as of 01/09/2017. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Formulary coverage does not imply efficacy or safety.

Making the prior authorization (PA) process easy

A tool that physicians and pharmacies can use to help complete PA requests. Visit covermymeds.com/main or call 1-866-452-5017 to learn more.

A web-based service, including a support staff, that helps physicians process and manage their PAs through to completion. Visit parxsolutions.com or call 1-866-725-7279 to learn more.

Allergan is commited to providing support for your patients and practice

To learn more about VIBERZI, contact Allergan Medical Information at 1-800-678-1605.

TOOLS FOR YOUR PRACTICE

The downloadable resources below are available to help you and your staff when speaking with or treating patients with IBS-D.

FOR YOUR PATIENTS

 

FOR YOUR PRACTICE

Sample Request Form

Use this form to request VIBERZI samples for your practice.

Not eligible where prohibited by law.

 

IBS-D INFORMATION

Ask Me Anything

This short video gives you and your staff a closer look at what IBS-D is like from a patient's perspective.

Next: REGISTRATION  

Contraindications

VIBERZI is contraindicated in patients:

Warnings and Precautions
Pancreatitis:
Sphincter of Oddi Spasm:
Hypersensitivity Reactions:
Constipation:
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.

 
IMPORTANT SAFETY INFORMATION
See More
Contraindications

VIBERZI is contraindicated in patients:

  • Without a gallbladder.
  • With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
  • With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
  • With a known hypersensitivity reaction to VIBERZI.
  • With severe hepatic impairment.
  • With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pancreatitis:
  • Pancreatitis, with or without sphincter of Oddi spasm, has been reported in patients taking either the 75 mg or 100 mg dosage of VIBERZI, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported in patients without a gallbladder. VIBERZI is contraindicated in patients without a gallbladder. Most of the reported cases of serious pancreatitis occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • In patients with a gallbladder, evaluate a patient’s alcohol intake prior to starting VIBERZI. Instruct patients to avoid chronic or acute excessive alcohol use while taking VIBERZI. Monitor for new or worsening abdominal pain that may radiate to the back or shoulder, with or without nausea and vomiting. Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of pancreatitis such as acute abdominal or epigastric pain radiating to the back or shoulder associated with elevations of pancreatic enzymes with or without nausea and vomiting.
Sphincter of Oddi Spasm:
  • There is a risk of sphincter of Oddi spasm, resulting in pancreatitis or hepatic enzyme elevation associated with acute abdominal pain (eg, biliary-type pain) in patients taking VIBERZI. Serious adverse reactions of sphincter of Oddi spasm with or without pancreatitis resulting in hospitalization have been reported, primarily in patients without a gallbladder. Cases of serious sphincter of Oddi spasm occurred within a week of starting treatment with VIBERZI and some patients developed symptoms after one to two doses.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of sphincter of Oddi spasm such as acute worsening of abdominal pain that may radiate to the back or shoulder with or without nausea and vomiting, associated with elevations of pancreatic enzymes or liver transaminases. Do not restart VIBERZI in patients who developed biliary duct obstruction while taking VIBERZI.
Hypersensitivity Reactions:
  • In postmarketing experience, serious hypersensitivity reactions (including anaphylaxis) have been reported following VIBERZI administration. Some of these reactions occurred after the first one or two doses of VIBERZI.
  • Instruct patients to immediately stop VIBERZI and seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction.
Constipation:
  • Constipation, sometimes requiring hospitalization, has been reported following VIBERZI administration. In postmarketing experience, severe cases with development of intestinal obstruction, intestinal perforation, and fecal impaction, requiring intervention, have also been reported. Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they experience severe constipation. Avoid use with other drugs that may cause constipation.
Adverse Reactions

The most commonly reported adverse reactions (incidence >5% and greater than placebo) were constipation, nausea, and abdominal pain.

Indication

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Please also see full Prescribing Information.